24 March 2002, The Economic Times

Arvind Remedies explores new markets
Amitabh Baxi

NEW DELHI: Chennai-based Arvind Remedies Ltd has chalked out a two-pronged strategy to explore new markets for its unique products that have been found to be extremely helpful in curing diseases like diabetes and bed sores.
In the first phase, the company plans to hit the over the counter segment in a big way for its products like Pankare and Sorexil.

"Led by a team of scientists, doctors and Ayurveda experts, Arvind Remedies has worked upon the herbal formulations as enunciated in Ayurveda and has developed a wonder drug, Pankare, which is a comprehensive combination of nine sanjeevinis and offers restoration, regeneration and rejuvenation of pancreatic Beta cells," Arvind Shah, managing director and CEO, Arvind Remedies, told ET.

The selected herbs in Pankare are scientifically and clinically proven to possess anti- diabetic properties by acting upon the pancreas by restoration and regeneration of pancreatic Beta cell activity.
The ingredients have also been found to possess anti-oxidant, anti-hypertensive and hypocholesterolemic properties in addition to the anti-diabetic property, he claimed.

Among its other innovative initiatives, Arvind Remedies has developed a unique product called Sorexil, a drug that treats bed sores and chronic ulcers, ailments, which hitherto had no cure.

The company is also in the advanced stage of developing unique products like Hartkare, which will remove blockages from arteries, a cancer drug, skin grafting drug and a drug for reducing obesity, among others.
Shah further said that the company was exporting its products in countries such as Malaysia, Sri Lanka, Vietnam, Zambia, Kenya and Nigeria, while the, formalities were almost complete in Ukraine.

The company is also in the process of obtaining an ISO 9002 Certification. It further plans to go in for newer molecules for ethical marketing, besides formulations based on latest generation molecules.
In the second phase, Arvind Remedies seeks to commission its second state-of-the-art plant by 2003, after which it plans to secure the US Federal Drug Authority, MCA of UK and TGA of Australia approvals. These would come as important milestones for expanding its global business.